Fabiana Zingone

Plain English
Researchers looked at how a supplement called Butyrate-Lsc-Microincapsulated (BLM) affects the gut bacteria and symptoms of inflammatory bowel disease (IBD) in 140 patients, including those with Crohn's disease and ulcerative colitis. They found that patients who took BLM experienced a significant decrease in disease activity and improved quality of life, particularly in those with Crohn's disease, with clinical symptoms improving at rates of about 13% (p=0.013) and a notable improvement in quality of life (p<0.001). This study highlights that modifying gut bacteria with a simple supplement can lead to better health outcomes for IBD patients. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at the best ways to diagnose and treat irritable bowel syndrome with diarrhea (IBS-D). Researchers found that instead of relying on extensive tests, doctors should focus on patients' symptoms and use new markers to improve diagnosis. Diet changes like low FODMAP and Mediterranean diets, along with therapies targeting the gut-brain connection, showed strong benefits in treatment, promoting a shift towards more personalized care. Who this helps: Patients with IBS-D can benefit from better diagnosis and targeted treatments.

Plain English
This study examined how diet affects gut health in people with inflammatory bowel diseases (IBD), like Crohn's disease and ulcerative colitis. It found that eating a healthy, high-fiber diet can lower disease risk, while ultra-processed foods make it worse. Specific nutritional plans, such as the Mediterranean diet, can help patients achieve better health and improve gut bacteria, which is important since up to 78% of IBD patients have nutrient deficiencies that worsen their condition. Who this helps: This benefits patients with inflammatory bowel disease by offering dietary strategies that can improve their health and quality of life.

Plain English
This study focused on new drugs for treating ulcerative colitis (UC), a lasting inflammatory bowel disease that affects an increasing number of people worldwide. Current treatments only help about 30-60% of patients, with some needing hospital care or surgery within five years. Researchers found over 100 new drugs in advanced testing, including medications that show promise with clinical remission rates higher than 25%, indicating that better treatment options are on the way. Who this helps: This helps patients with moderate to severe ulcerative colitis.

Plain English
This study looked at how well patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) followed the Mediterranean Diet and how much highly processed food they ate. Researchers found that CD patients followed the Mediterranean Diet less than UC patients, with scores of 9.3 compared to 9.8, and that higher intake of processed foods was linked to worse metabolic health. This matters because adopting healthier eating habits could improve the health of individuals with inflammatory bowel diseases. Who this helps: Patients with Crohn's Disease and Ulcerative Colitis.

Plain English
Researchers updated the guidelines for diagnosing and managing coeliac disease (CeD) in adults. The new recommendations include safe ways to include oats in the diet, approaches for managing persistent symptoms, and new treatment options for patients who don’t respond to the typical gluten-free diet. These changes aim to improve patient care and health outcomes by using the latest scientific findings to create more personalized treatment plans. Who this helps: This helps adults with coeliac disease and their healthcare providers.

Plain English
This study looked at how well three treatments—vedolizumab, ustekinumab, and Janus kinase inhibitors (JAKis)—work for patients with ulcerative colitis who had not responded to another treatment called anti-TNF-α. Researchers found that ustekinumab and JAKis led to higher rates of remission after 12 months compared to vedolizumab, with ustekinumab showing 54% better chances for clinical remission and JAKis showing 66% better chances. However, JAKis also had a much higher risk of side effects, about four times more than the other treatments. Who this helps: This information benefits patients with ulcerative colitis and their doctors by guiding treatment choices after initial therapies fail.

Plain English
This study looked at how celiac disease affects people’s ability to work and the reasons they miss work. Out of 167 patients, 14% missed work in the past month, averaging about 6.6 hours lost. Those who missed work experienced more ongoing symptoms, higher depression levels, and a lower quality of life compared to those who did not miss work, showing that persistent symptoms and being on a gluten-free diet for less than a year are key factors. Who this helps: This information benefits patients with celiac disease and their doctors.

Plain English
This study focused on autoimmune atrophic gastritis (AAG), a condition where the immune system attacks the stomach lining, leading to problems like low stomach acid and difficulty absorbing important nutrients. The authors noted that many patients are often misdiagnosed or experience delays in their diagnosis, which can lead to serious health issues, including anemia and an increased risk of stomach cancer. Understanding AAG better is crucial for prompt diagnosis and better treatment, which can improve patients' health and reduce related healthcare costs. Who this helps: This helps patients with autoimmune gastritis and their doctors.

Plain English
This study looked at two rare types of intestinal lymphomas, B-cell and T-cell, to understand their clinical features and survival rates. The researchers found that B-cell lymphomas are usually diagnosed earlier and patients live much longer, with a median follow-up showing a survival rate more than five times better than T-cell lymphomas (56 months for B-cell compared to only 12 months for T-cell). It’s important because understanding these differences can help doctors choose better treatments and care plans for patients. Who this helps: This helps patients with intestinal lymphomas and their doctors.

Plain English
This study looked at how common sexual dysfunction (SD) is among adults with inflammatory bowel disease (IBD). The researchers found that over half (50.6%) of IBD patients experienced sexual dysfunction, with even higher rates in specific groups: 64.8% in those with ulcerative colitis and 58.3% in those with Crohn's disease. This is important because it highlights a significant quality of life issue that is often overlooked for these patients, suggesting that doctors should actively screen for and address these problems. Who this helps: This helps patients with inflammatory bowel disease, particularly women and those with active disease.

Plain English
This study looked at how well frozen stool samples work for treating repeated C. difficile infections over a longer period of time, specifically up to 24 months. The researchers found that frozen samples still contained healthy bacteria and were effective in 71.4% of patients after one year, and 100% by the end of the study, showing that freezing does not significantly impact treatment success. This is important because it means doctors can use frozen stool more easily, allowing more patients to benefit from FMT without losing effectiveness. Who this helps: Patients suffering from recurrent C. difficile infections.

Plain English
This research paper looks at how diet can help manage Inflammatory Bowel Disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The study found that certain diets, like Exclusive Enteral Nutrition for children with CD and the Mediterranean Diet for everyone, can improve health and reduce symptoms. It highlights that nutritional support is important, especially for hospitalized patients, and urges the need for more focused research to create effective dietary guidelines for IBD patients. Who this helps: This research benefits patients with Inflammatory Bowel Disease and their healthcare providers.

Plain English
This study looked at how the bacteria in our mouths and esophagus might help treat Eosinophilic Esophagitis (EoE), a condition that causes symptoms like difficulty swallowing and heartburn. The research found that adjusting these bacteria, possibly through probiotic treatments, could improve treatment effectiveness and increase the chances of patients feeling better without adding side effects. Understanding the role of the esophageal microbiome could lead to better management of EoE. Who this helps: This helps patients with Eosinophilic Esophagitis.

Plain English
This study looked at the appendix in patients with ulcerative colitis (UC) to understand how bacteria and immune cells are related. Researchers found that while the diversity of bacteria was similar in the appendices of UC patients and those without UC, some specific bacterial species were much less common in UC patients. Additionally, UC patients had more activated dendritic cells, which are important for the immune response and were linked to higher stool frequency, indicating a potential role of these immune cells in UC flare-ups. Who this helps: This benefits patients with ulcerative colitis and their healthcare providers by providing insights into the disease's immune mechanisms.

Plain English
This study looked at how common celiac disease (CeD) is in people with primary biliary cholangitis (PBC), a chronic liver condition. Out of over 15,000 patients with PBC, only 286 (about 1.9%) were diagnosed with CeD, which is similar to the general population's rate of around 1%. This matters because it indicates that testing everyone with PBC for CeD may not be necessary. Who this helps: This helps doctors and patients with PBC by clarifying that routine screening for celiac disease is not needed.

Plain English
This study looked at how gut bacteria affect brain health in neurological diseases. Researchers found that short-chain fatty acids (SCFAs), produced by these gut bacteria, are linked to conditions like Parkinson's and Alzheimer's. For example, patients with Parkinson’s showed lower levels of bacteria that produce butyrate, and Alzheimer's patients had significant drops in key SCFAs, highlighting the importance of gut health in brain function. Understanding this connection may lead to better treatments by targeting gut bacteria, offering new hope for patients with these neurological disorders. Who this helps: This helps patients with neurological diseases, their doctors, and researchers looking for new therapies.

Plain English
This study looked at the gut bacteria (microbiota) of patients with colitis caused by immune checkpoint inhibitors (ICIs), a type of cancer treatment, and compared it to patients with inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis, as well as healthy individuals. The researchers found that the gut bacteria profile of the ICI-colitis patients was significantly different from those with IBD, showing that machine learning can effectively identify these differences. This matters because it may help doctors diagnose ICI-colitis more accurately and improve treatment strategies for patients facing these immune-related side effects. Who this helps: Patients undergoing treatment with immune checkpoint inhibitors.

Plain English
This study looked at how accurate blood tests are for diagnosing Dermatitis Herpetiformis (DH), a skin condition related to gluten. Researchers reviewed 25 studies and found that certain tests, like the ELISA for IgA-tTG, were good at identifying DH cases (90% sensitivity), but not very reliable in ruling it out (only 14% specificity). The findings emphasize the importance of considering whether a patient is on a gluten-free diet, as this significantly impacts test results, and using the right combination of tests can lead to better diagnoses and treatment. Who this helps: Patients with Dermatitis Herpetiformis and their doctors.

Plain English
This study looked at how well doctors manage the return of Crohn's disease symptoms after surgery, a challenge many patients face. Researchers found that around 39.5% of patients experience a recurrence ten years after surgery, with a high chance (22.4-53%) of finding signs of the disease again within 18-36 months. Understanding factors like genetics and lifestyle choices, along with new monitoring techniques and effective treatments, can help tailor better care for these patients, reducing the impact of the disease. Who this helps: This helps patients with Crohn's disease, especially those who have had surgery.

Plain English
This study looked at three advanced language models—ChatGPT-4, Claude 3.7, and Gemini 2.0—to see how well they provide accurate and clear information about celiac disease. Researchers found that Gemini 2.0 had the highest accuracy ratings (4.5 out of 5) and clarity scores (5 out of 5), and it was easier to read, needing about 2-3 fewer years of education to understand compared to the others. However, there's still a problem with misinformation, which ranged from 13.3% to 24.2% across all models, indicating that caution is needed when using these tools for patient education. Who this helps: This benefits patients and healthcare providers who want reliable information about managing celiac disease.

Plain English
The 2025 updated guidelines from the European Society for the Study of Coeliac Disease focus on improving how doctors diagnose coeliac disease in adults. Key changes include allowing some patients with high levels of a specific antibody to avoid a biopsy and emphasizing the use of accurate blood tests instead of older methods for confirming the disease. These updates are important because they aim to make diagnoses more accurate and less invasive, ultimately leading to better care and quality of life for patients. Who this helps: This helps patients with suspected coeliac disease and their healthcare providers.

Plain English
This study examined whether testing for two specific antibodies, tTG IgA and DGP IgG, can accurately diagnose celiac disease without needing a biopsy. Researchers found that if patients tested positive for both antibodies at high levels, the likelihood of actually having celiac disease was very high—92.5% for any positive and 100% for those with extremely high levels. This is important because it offers a less invasive and simpler way to diagnose celiac disease, potentially improving patient care. Who this helps: This benefits patients suspected of having celiac disease, making diagnosis easier and less intrusive.

Plain English
This study looked at the long-term health outcomes of patients with nonceliac enteropathies (NCEs), which are digestive disorders not related to celiac disease, over a period of 30 years. Researchers found that 10 years after diagnosis, about 74% of patients were still alive, but mortality rates were significantly higher for these patients compared to the general population, with a mortality rate about three times higher. They created a scoring system to identify patients at higher risk of serious health issues, allowing for better monitoring and personalized treatment plans. Who this helps: This research benefits patients with nonceliac enteropathies and their doctors by providing insights for better management and care.

Plain English
This research paper looks at how gut bacteria affect inflammatory bowel disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. Researchers found that understanding and managing gut microbiota can significantly improve diagnostic methods and treatments for IBD. For example, personalized therapies based on a patient’s specific gut bacteria profile are becoming more common, potentially leading to better outcomes for patients. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study looked at oxidative stress in two types of atrophic gastritis: autoimmune atrophic gastritis (AAG) and multifocal atrophic gastritis (MAG), involving 120 patients. The researchers found that while oxidative stress markers were similar between the two types, those with early-stage AAG had higher oxidative stress than those with advanced AAG, and 8-OHdG levels (a marker of DNA damage) were significantly higher in MAG patients compared to AAG patients, indicating more genomic damage in MAG. Understanding these differences is crucial as it suggests that patients with AAG may have a lower risk of developing tumors compared to those with MAG. Who this helps: This information benefits patients with atrophic gastritis and their doctors by informing treatment approaches and cancer risk assessments.

Plain English
This study examined two types of atrophic gastritis—multifocal (MF-AG) and corpus-restricted (CR-AG)—in patients who also had non-cardia gastric cancer (GC) or precancerous changes (dysplasia). Out of 84 patients, 56% had cancer, with similar rates observed in both types of atrophic gastritis. However, the cancer tended to appear more often as polyp-like growths in CR-AG patients, leading to more frequent surgeries compared to those with MF-AG. Who this helps: This research benefits doctors managing patients at risk for gastric cancer.

Plain English
This study focused on how the blood vessels in the esophagus are affected in patients with eosinophilic esophagitis (EoE), a condition where the immune system causes inflammation in the esophagus. Researchers found that, in EoE patients, blood vessel barriers were leaking, while this was not the case in patients with reflux esophagitis or healthy individuals. In fact, levels of a specific marker for blood vessel integrity were significantly higher in EoE patients, showing that an active form of this condition disrupts the esophageal vascular barrier. Who this helps: This information benefits patients with eosinophilic esophagitis and their doctors in understanding the condition better.

Plain English
This study looked at how autoimmune gastritis (AIG) manifests in children under 18 years old. The researchers reviewed data from 51 patients and found that 92% had the most serious form of AIG, with a variety of related conditions like atopic dermatitis and asthma observed in some patients. Most notably, only one child had a Helicobacter pylori infection, which is often linked to stomach issues, suggesting a different cause for AIG in kids. Who this helps: This information benefits pediatricians and healthcare providers by improving understanding and diagnosis of AIG in young patients.

Plain English
This study looked at two types of serious cancers linked to celiac disease: small bowel adenocarcinoma (SBA) and T-cell lymphoma (TCL). Researchers found that patients with SBA had a much better chance of surviving than those with TCL, with survival rates significantly different between the two groups. Specifically, 70% of TCL patients did not respond to a gluten-free diet, while only one patient with SBA did not benefit from it. This research highlights the need for different approaches in treating these two cancer types. Who this helps: This helps doctors and patients dealing with celiac disease and its associated cancers.

Plain English
This study examined how to best diagnose and treat gastroesophageal reflux disease (GERD) by gathering insights from five Italian medical societies. The experts agreed on 27 key recommendations, emphasizing a symptom-based approach for diagnosis and suggesting specific treatments, such as a standard 4-8 week course of proton pump inhibitors (PPIs) for most patients. These guidelines matter because they provide clear direction on managing GERD, helping to improve patient care and outcomes. Who this helps: This helps doctors and patients with GERD.

Plain English
This research focused on creating guidelines for diagnosing and treating functional dyspepsia (FD), a common digestive disorder affecting many people. Experts from five Italian medical societies came together to agree on 24 key points about how to diagnose and manage FD, including the recommendation that patients over 45 should get an endoscopy to rule out other conditions. They found that a standard dose of proton pump inhibitors (PPIs) is effective as the first line of treatment, while other approaches, like dietary restrictions and certain medications, were not widely agreed upon. Who this helps: These guidelines benefit doctors and healthcare providers who treat patients with functional dyspepsia.

Plain English
Researchers adapted European quality care standards for inflammatory bowel disease (IBD) to better fit Italy's healthcare system. They started with 101 statements from the European Crohn's Colitis Organisation and created 112 tailored criteria for Italian care, confirming 80 of the original statements while adding 12 new ones. This is important because it aims to improve the consistency and quality of IBD treatment in Italy, which can lead to better patient outcomes. Who this helps: Patients with inflammatory bowel disease in Italy.

Plain English
This study looked at how certain treatment and biomarker levels relate to success in managing Crohn's disease in patients taking a drug called Ustekinumab (UST). Researchers found that after 52 weeks, 47% of patients achieved a significant improvement in their condition measured by a specific test, and 61.8% had overall clinical improvement. They also found that UST levels measured after the second dose were linked to biochemical improvement, which indicates that tracking these levels could help better manage treatment. Who this helps: This information benefits patients with Crohn's disease and their doctors by providing insights into monitoring treatment effectiveness.

Plain English
This study looked at how inflammatory bowel disease (IBD) affects women's reproductive health. It involved 457 women, with 228 having IBD and 229 being healthy. The findings showed that women with IBD were twice as likely to have spontaneous abortions and over three times more likely to experience voluntary abortions. Additionally, if a woman with IBD had a flare-up during pregnancy, the risk of complications was more than six times higher compared to those in remission, and their chances of breastfeeding were 66% lower. Who this helps: This helps women with IBD and their healthcare providers by highlighting the need for better reproductive health support.

Plain English
This study looked at how beneficial substances called short-chain fatty acids (SCFAs), which are made when gut bacteria break down certain dietary fibers, impact human health. Researchers found that SCFAs, particularly butyrate, play important roles in preventing and treating problems related to digestion, metabolism, and even brain health. Understanding how these substances are produced and absorbed in the gut can lead to better treatments for various health issues. Who this helps: This helps patients with gastrointestinal, metabolic, cardiovascular, and mental health conditions.

Plain English
This study looked at how effective certain rectal suppositories—containing Palmitoylethanolamide, Epilobium, and Calendula—are for treating men with chronic pelvic pain linked to prostatitis. Researchers followed 45 men with ongoing pelvic pain for at least three months. After one month of treatment, they found significant improvements in several health measures: the average symptom score (NIH-CPSI) dropped from 18.55 to a lower score, urinary white blood cells decreased, and other health indicators like peak flow improved, showing that these suppositories can help reduce pain and inflammation. Who this helps: Patients suffering from chronic prostatitis and related pelvic pain.

Plain English
This study focused on semaglutide, a medication that belongs to a class called GLP-1 receptor agonists, and its effects on patients with chronic kidney disease (CKD) and type 2 diabetes. Researchers found that semaglutide could help protect the kidneys and heart, but many patients still struggle to respond to other available treatments. Since CKD affects about 10% of the global population and contributes significantly to premature death, understanding how semaglutide works is crucial for improving patient care. Who this helps: This research helps patients with chronic kidney disease and type 2 diabetes.

Plain English
This study explored the proteins in saliva to understand how inflammatory bowel diseases (IBD) like Crohn's disease and colorectal cancer (CRC) may be connected. Researchers found 152 proteins in saliva, with 73 of them present in both IBD and CRC patients, indicating a shared pathway involving cell adhesion and immune response. The presence of certain proteins in the stool of patients with Crohn's disease was linked to cell growth, suggesting that these proteins might contribute to cancer development. Who this helps: This research helps patients with inflammatory bowel diseases and colorectal cancer by providing insights into their conditions.

Plain English
This study looked at how inflammatory bowel diseases (like ulcerative colitis and Crohn's disease) and spondyloarthritis (a type of arthritis) affect women. The researchers found that many women are often misdiagnosed, with IBD being confused with irritable bowel syndrome and SpA mistaken for fibromyalgia. This misdiagnosis can lead to delays in treatment, worsening the patients' health and overall quality of life. The authors highlight the importance of better diagnostic tools and collaboration between doctors to improve care for these women. Who this helps: This helps female patients suffering from inflammatory bowel diseases and spondyloarthritis.

Plain English
This study looked at Crohn's Disease (CD), a long-lasting condition that causes inflammation in the intestines, making patients experience painful flare-ups and periods of no symptoms. Researchers found that even with new treatments, many patients do not find relief, leading to ongoing health issues and high healthcare costs, especially in the first year after being diagnosed. Exploring new therapies, such as stem cell treatments and dietary changes, is crucial to helping those who aren't responding to current options. Who this helps: This benefits patients suffering from stubborn Crohn's Disease that doesn’t improve with existing treatments.

Plain English
This study looked at a new, easier test for measuring the drug levels of infliximab and adalimumab—two medications used to treat inflammatory bowel disease (IBD)—and compared it to the standard lab test, ELISA. The new test showed a strong agreement with the ELISA results, with a correlation score of 0.83 for infliximab and 0.85 for adalimumab, while also providing results much faster. This matters because it could help doctors make quicker treatment decisions for IBD patients, improving care without the delays of traditional testing methods. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at how a specific probiotic product, DG®, affects inflammation in the pouch or intestine of patients who have undergone surgery for conditions like ulcerative colitis. Researchers found that after taking DG® for eight weeks, patients experienced significant reductions in inflammatory markers compared to those who received a placebo. This is important because it indicates that probiotics can help improve the health of the intestinal pouch and potentially prevent complications. Who this helps: This benefits patients recovering from restorative proctocolectomy, particularly those at risk of pouchitis.

Plain English
This study reviews new and experimental drugs aimed at treating Crohn's disease, a long-lasting inflammation in the digestive system. Recent clinical trials show that many current treatments don't work well for over 60% of patients, prompting the need for new approaches. The researchers highlight various promising therapies that target different biological processes, aiming to create better treatment options for patients suffering from this condition. Who this helps: This benefits patients with Crohn's disease and their doctors by providing more effective treatment options.

Plain English
In this study, researchers looked at how well adults with coeliac disease (a condition that requires a strict gluten-free diet) can bounce back from challenges in life. They found that 98% of the 305 patients had a high level of resilience. However, those with higher anxiety and depression tended to have lower resilience, indicating that addressing these mental health issues could help improve their overall well-being. Who this helps: This research benefits patients with coeliac disease and healthcare providers managing their care.

Plain English
This study looked at the experiences of female gastroenterologists in Italy through a survey of 423 doctors. The findings showed that while 76.8% were employed full-time, only 7.2% had academic positions, and a significant 58% felt undervalued, mainly due to gender bias. This matters because it highlights ongoing inequalities in the field of gastroenterology, which can affect career progression and patient care. Who this helps: This helps female gastroenterologists and patients who benefit from a more diverse and equitable healthcare workforce.

Plain English
Researchers studied patients with autoimmune gastritis (AIG) to understand how previous infections with Helicobacter pylori (a type of bacteria) or specific antibodies affect their health. They found that only 0.9% of patients developed gastric cancer, while 9.6% developed a type of tumor called gastric neuroendocrine neoplasm (gNEN), with a higher risk for those showing vitamin B12 deficiency at the time of diagnosis. This information is important because it helps identify which patients might need closer monitoring, particularly those with vitamin B12 issues. Who this helps: Patients with autoimmune gastritis and their doctors.

Plain English
The paper outlines new guidelines for diagnosing and managing eosinophilic esophagitis (EoE), a condition where the esophagus is inflamed due to a high number of certain white blood cells. The guidelines were created by a group of experts in Italy and stress effective treatment options and monitoring methods. It highlights important areas for future research and has been supported by major Italian medical societies. Who this helps: This helps patients with eosinophilic esophagitis and their healthcare providers.